Alan Sandler, MD, division chief of Hematology and Medical Oncology at Oregon Health & Science University, explains that many lung cancer experts and thought leaders may have dismissed the possibility of using immunotherapies to treat lung cancer; however, these therapies are gradually becoming more of a reality.

There are currently trials investigating several immune targeted therapies for lung cancer. Sandler highlights a few, including those looking at BMS-936558, a novel agent that targets the programmed death-1 (PD-1) pathway, another using the agent talactoferrin, an oral immunotherapy, and multiple vaccines that are currently under investigation.

Many of these trials are still in early phases, Sandler notes, but they show that the hypothesis of using an immunotherapy for lung cancer is currently being tested using the current generation of treatments. To date, the data seems promising that these newer therapies are effective.

In general, Sandler notes that the recent success of immunotherapies in lung cancer has come as a surprise. Although, he adds that as techniques improve what is possible continues to evolve. As an example, he notes that in the 1980s the idea of using antibodies seemed far-fetched, but they are now the main stay of many therapies.

Videos

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

Dr. Sandler on Immunotherapies to Treat Lung Cancer

Alan Sandler, MD, division chief of Hematology and Medical Oncology at Oregon Health & Science University, discusses the mechanism of action for tivantinib (formally ARQ 197), an oral, small molecule, c-Met inhibitor currently being investigated in several trials, including MARQUEE, a phase III trial for patients with advanced, non-squamous, non-small cell lung cancer. 

Sandler explains that the overexpression of the c-Met protein is associated with malignant tumor growth and has been linked to increased proliferation, invasion, metastasis, tumor angiogenesis and decreased tumor apoptosis. Additionally, the overexpression of c-Met has been implicated in the malignant growth of multiple tumors, making it an important anticancer target. 

The agent tivantinib is thought to prevent the downstream effects of c-Met overexpression, by binding to the c-Met receptor, which disrupts the c-Met signal transduction pathways.  

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action


Alan Sandler, MD

Articles

Dr. Sandler on Immunotherapies to Treat Lung Cancer

Dr. Sandler Discusses the Tivantinib Mechanism of Action